Information de reference pour ce titreAccession Number: | 00078447-201806100-00011.
|
Author: | Li, Na; Taylor, Lynne S. *
|
Institution: | Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, United States
|
Title: | Tailoring supersaturation from amorphous solid dispersions.[Article]
|
Source: | Journal of Controlled Release. 279:114-125, June 10, 2018.
|
Abstract: | The maximum achievable concentration of a drug in solution is dictated by the chemical potential of the solid form. Because an amorphous solid has a higher chemical potential than the corresponding crystal form, in the absence of phase transformations, a higher transient solubility is expected. However, the chemical potential of an amorphous drug can be reduced by mixing with another component. Therefore, upon mixing with a polymer to form an amorphous solid dispersion (ASD), the maximum solution concentration achieved can be potentially altered, in particular if the polymer is poorly soluble in the dissolution medium. Such changes in the chemical potential of the drug may be a critical factor in determining the maximum achievable solution concentration, and could alter the crystallization driving force of the drug. Therefore, the aim of this study was to gain insights into the impact of poorly soluble polymers on the "amorphous solubility" of drugs formulated as amorphous solid dispersions. Lopinavir was selected as a model drug with a low crystallization tendency, enabling determination of the amorphous solubility as a function of ASD composition. Model polymers included cellulose acetate (CA), CA phthalate (CAP), ethylcellulose (EC), Eudragit(R) RL PO (EUD), hydroxypropylmethylcellulose (HPMC), HPMC acetate succinate (HPMCAS), and HPMC phthalate (HPMCP). The "amorphous solubility" of the drug alone was determined and then the changes in maximum achievable concentration were measured as a function of drug loading. Drug-polymer interactions were characterized using infrared spectroscopy (IR), differential scanning calorimetry (DSC) and moisture sorption analysis. The results showed that the maximum achievable concentration ("amorphous solubility") of lopinavir varied with the extent of drug-polymer interactions, as well as the drug weight fraction in the ASD. This information is of great value when evaluating the maximum achievable concentration of amorphous systems formulated with pH responsive polymers, and should contribute to a broader understanding of drug phase behavior in the context of ASDs.
(C) 2018Elsevier, Inc.
|
Author Keywords: | Solubility; Miscibility; Drug release; Polymer; Thermodynamics.
|
References: | [1] L. Di, E.H. Kerns, G.T. Carter, Drug-like property concepts in pharmaceutical design. Curr. Pharm. Des. 2009;15:2184-2194.
[2] L. Di, P.V. Fish, T. Mano, Bridging solubility between drug discovery and development. Drug Discov. Today. 2012;17:486-495.
[3] C.A. Lipinski, Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. 2000;44:235-249.
[4] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997;23:3-25.
[5] C. Leuner, J. Dressman, Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000;50:47-60.
[6] P.H. Elworthy, M.S. Patel, Demonstration of maximum solubilization in a polyoxyethylene alkyl ether series of non-ionic surfactants. J. Pharm. Pharmacol. 1982;34:543-546.
[7] J.M. Miller, A. Beig, R.A. Carr, G.K. Webster, A. Dahan, The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. Mol. Pharm. 2012;9:581-590.
[8] T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996;85:1017-1025.
[9] A. Dahan, A. Beig, D. Lindley, J.M. Miller, The solubility-permeability interplay and oral drug formulation design: two heads are better than one. Adv. Drug Deliv. Rev. 2016;101:99-107.
[10] S. Raina, G.Z. Zhang, D. Alonzo, J. Wu, D. Zhu, N. Catron, Y. Gao, L.S. Taylor, Impact of solubilizing additives on supersaturation and membrane transport of drugs. Pharm. Res. 2015;32:1-15.
[11] J.M. Miller, A. Beig, R.A. Carr, J.K. Spence, A. Dahan, A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol. Pharm. 2012;9:2009-2016.
[12] M. Yoshioka, B.C. Hancock, G. Zografi, Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci. 1995;84:983-986.
[13] G.A. Ilevbare, H. Liu, K.J. Edgar, L.S. Taylor, Impact of polymers on crystal growth rate of structurally diverse compounds from aqueous solution. Mol. Pharm. 2013;10:2381-2393.
[14] G.A. Ilevbare, H. Liu, K.J. Edgar, L.S. Taylor, Maintaining supersaturation in aqueous drug solutions: impact of different polymers on induction times. Cryst. Growth Des. 2012;13:740-751.
[15] W. Curatolo, J.A. Nightingale, S.M. Herbig, Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm. Res. 2009;26:1419-1431.
[16] C. Aitken-Nichol, F. Zhang, J.W. McGinity, Hot melt extrusion of acrylic films. Pharm. Res. 1996;13:804-808.
[17] J. Huang, R.J. Wigent, J.B. Schwartz, Nifedipine molecular dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blends for controlled drug delivery: effect of matrix composition. Drug Dev. Ind. Pharm. 2006;32:1185-1197.
[18] J. Desai, K. Alexander, A. Riga, Characterization of polymeric dispersions of dimenhydrinate in ethyl cellulose for controlled release. Int. J. Pharm. 2006;308:115-123.
[19] Z. Iqbal, A. Babar, M. Ashraf, Controlled-release naproxen using micronized ethyl cellulose by wet-granulation and solid-dispersion method. Drug Dev. Ind. Pharm. 2002;28:129-134.
[20] F.A. Maulvi, D.H. Lakdawala, A.A. Shaikh, A.R. Desai, H.H. Choksi, R.J. Vaidya, K.M. Ranch, A.R. Koli, B.A. Vyas, D.O. Shah, In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery. J. Control. Release. 2016;226:47-56.
[21] D.D. Sun, P.I. Lee, Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers. J. Control. Release. 2015;211:85-93.
[22] T. Ohara, S. Kitamura, T. Kitagawa, K. Terada, Dissolution mechanism of poorly water-soluble drug from extended release solid dispersion system with ethylcellulose and hydroxypropylmethylcellulose. Int. J. Pharm. 2005;302:95-102.
[23] N. Li, J.D. Ormes, L.S. Taylor, Leaching of lopinavir amorphous solid dispersions in acidic media. Pharm. Res. 2016;33:1-13.
[24] G.A. Ilevbare, L.S. Taylor, Liquid-liquid phase separation in highly supersaturated aqueous solutions of poorly water-soluble drugs: implications for solubility enhancing formulations. Cryst. Growth Des. 2013;13:1497-1509.
[25] S.B. Murdande, M.J. Pikal, R.M. Shanker, R.H. Bogner, Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J. Pharm. Sci. 2010;99:1254-1264.
[26] L. Almeida e Sousa, S.M. Reutzel-Edens, G.A. Stephenson, L.S. Taylor, Assessment of the amorphous "solubility" of a group of diverse drugs using new experimental and theoretical approaches. Mol. Pharm. 2014;12:484-495.
[27] S.B. Murdande, M.J. Pikal, R.M. Shanker, R.H. Bogner, Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm. Res. 2010;27:2704-2714.
[28] N.S. Trasi, L.S. Taylor, Dissolution performance of binary amorphous drug combinations-impact of a second drug on the maximum achievable supersaturation. Int. J. Pharm. 2015;496:282-290.
[29] N.S. Trasi, L.S. Taylor, Thermodynamics of highly supersaturated aqueous solutions of poorly water-soluble drugs-impact of a second drug on the solution phase behavior and implications for combination products, J. Pharm. Sci. (2015) 2583-2593.
[30] S. Huang, C. Mao, R.O. Williams III, C.-Y. Yang, Solubility advantage (and disadvantage) of pharmaceutical amorphous solid dispersions. J. Pharm. Sci. 2016;105:3549-3561.
[31] J. Van Den Abeele, J. Rubbens, J. Brouwers, P. Augustijns, The dynamic gastric environment and its impact on drug and formulation behaviour. Eur. J. Pharm. Sci. 2017;96:207-231.
[32] N. Li, L.I. Mosquera-Giraldo, C.H. Borca, J. Ormes, M. Lowinger, J. Higgins, L.V. Slipchenko, L.S. Taylor, A comparison of the crystallization inhibition properties of bile salts, Cryst. Growth Des. (12) (2016) 7286-7300.
[33] L. Greenspan, Humidity fixed points of binary saturated aqueous solutions. J. Res. Natl. Bur. Stand. Sect. A. 1977;81:89-96.
[34] T.P. Garcia, Ester Hydrolysis of Cellulose Acetate and Cellulose Acetate Phthalate in Aqueous Suspension and Solution, and Solid State. (Doctoral Dissertation). 1989. Department of Indsutrial and Physical Pharmacy, Purdue University.
[35] G.M. Gantz, J.B. Batdorf, Stabilization of ethyl cellulose against photo oxidation. J. Photogr. Sci. 1959;7:35-38.
[36] P. Roxin, A. Karlsson, S.K. Singh, Characterization of cellulose acetate phthalate (CAP). Drug Dev. Ind. Pharm. 1998;24:1025-1041.
[37] D. Lin-Vien, N.B. Colthup, W.G. Fateley, J.G. Grasselli, The Handbook of Infrared and Raman Characteristic Frequencies of Organic Molecules; 1991.
[38] K.J. Crowley, G. Zografi, Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J. Pharm. Sci. 2002;91:2150-2165.
[39] G.S. Parks, L.J. Snyder, F.R. Cattoir, Studies on glass. XI. Some thermodynamic relations of glassy and alpha-crystalline glucose. J. Chem. Phys. 1934;2:595-598.
[40] B. Hancock, M. Parks, What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 2000;17:397-404.
[41] M.C. Brick, H.J. Palmer, T.H. Whitesides, Formation of colloidal dispersions of organic materials in aqueous media by solvent shifting. Langmuir. 2003;19:6367-6380.
[42] L.I. Mosquera-Giraldo, L.S. Taylor, Glass-liquid phase separation in highly supersaturated aqueous solutions of telaprevir. Mol. Pharm. 2015;12:496-503.
[43] A.S. Indulkar, K.J. Box, R. Taylor, R. Ruiz, L.S. Taylor, pH-dependent liquid-liquid phase separation of highly supersaturated solutions of weakly basic drugs. Mol. Pharm. 2015;12:2365-2377.
[44] P.J. Flory, 1953. Principles of Polymer Chemistry, Cornell University Press.
[45] P. Marsac, S. Shamblin, L.S. Taylor, Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 2006;23:2417-2426.
[46] A.C.F. Rumondor, H. Konno, P.J. Marsac, L.S. Taylor, Analysis of the moisture sorption behavior of amorphous drug-polymer blends. J. Appl. Polym. Sci. 2010;117:1055-1063.
[47] A.P. Simonelli, S.C. Mehta, W.I. Higuchi, Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J. Pharm. Sci. 1969;58:538-549.
[48] Y. Chen, S. Wang, S. Wang, C. Liu, C. Su, M. Hageman, M. Hussain, R. Haskell, K. Stefanski, F. Qian, Initial drug dissolution from amorphous solid dispersions controlled by polymer dissolution and drug-polymer interaction. Pharm. Res. 2016;33:2445-2458.
[49] A.S. Indulkar, J.E. Waters, H. Mo, Y. Gao, S.A. Raina, G.G.Z. Zhang, L.S. Taylor, Origin of Nanodroplet formation upon dissolution of an amorphous solid dispersion: a mechanistic isotope scrambling study. J. Pharm. Sci. 2017;106:1998-2008.
[50] Shin-Etsu, Shin-Etsu Pharmaceutical Excipients Product Table. http://www.se-pfmd.com/getfile.p...- ouverture dans une nouvelle fenêtre.
[51] Dow, Dow cellulosics: ETHOCEL ethylcellulose polymers technical handbook. http://msdssearch.dow.com/Publis...- ouverture dans une nouvelle fenêtre.
[52] L.I. Mosquera-Giraldo, C.H. Borca, X. Meng, K.J. Edgar, L.V. Slipchenko, L.S. Taylor, Mechanistic design of chemically diverse polymers with applications in oral drug delivery. Biomacromolecules. 2016;17:3659-3671.
|
Language: | English.
|
Document Type: | Articles.
|
Journal Subset: | Pharmacology.
|
ISSN: | 0168-3659
|
DOI Number: | https://dx.doi.org/10.1016/j.jco...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|